4.0 Review

Translational Research in Neurology and Neuroscience 2011

Journal

ARCHIVES OF NEUROLOGY
Volume 68, Issue 6, Pages 709-716

Publisher

AMER MEDICAL ASSOC
DOI: 10.1001/archneurol.2011.11

Keywords

-

Funding

  1. Volkswagen Foundation
  2. Hermann and Lilly Schilling Foundation
  3. National Institute of Neurological Disorders and Stroke
  4. CHDI
  5. Canadian Research Chair Program
  6. Parkinson Research Consortium of Ottawa
  7. Jack Clark Chair in Parkinson's Disease Research at the University of Toronto

Ask authors/readers for more resources

We provide an update on the state of translational research in movement disorders, using examples of Huntington disease, Parkinson disease, and dystonia. While substantial progress in our understanding of these disorders has been achieved, development of neuroprotective treatments remains an unrealized goal. Here we highlight some of the emerging research areas that show the most promise for translational research in Huntington disease, Parkinson disease, and dystonia. Aetiology and pathogenesis, biomarker directions, and causal treatment opportunities are discussed for each disease, followed by a brief discussion drawing attention to important translational initiatives. Arch Neurol. 2011; 68(6):709-716. Published online February 14, 2011. doi:10.1001/archneurol.2011.11

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Clinical Neurology

Mosaic divergent repeat interruptions in XDP influence repeat stability and disease onset

Joanne Trinh, Theresa Luth, Susen Schaake, Bjorn-Hergen Laabs, Kathleen Schlueter, Joshua Lass, Jelena Pozojevic, Ronnie Tse, Inke Koenig, Roland Dominic Jamora, Raymond L. Rosales, Norbert Brueggemann, Gerard Saranza, Cid Czarina E. Diesta, Frank J. Kaiser, Christel Depienne, Christopher E. Pearson, Ana Westenberger, Christine Klein

Summary: By sequencing the genomes of XDP patients, researchers have discovered various mutations within the repetitive sequence SINE-VNTR-Alu(AGAGGG)(n), which may act as modifiers of disease expression in XDP.

BRAIN (2023)

Article Genetics & Heredity

MRM2 variants in families with complex dystonic syndromes: evidence for phenotypic heterogeneity

Anum Shafique, Beenish Arif, Mary Lynn Chu, Ellen Moran, Tooba Hussain, Francisca Millan Zamora, Elizabeth Wohler, Nara Sobreira, Christine Klein, Katja Lohmann, Sadaf Naz

Summary: This study investigated patients with dystonic or involuntary movement disorders in two families. Genetic analyses revealed mutations in the MRM2 gene that were associated with the phenotypes.

JOURNAL OF MEDICAL GENETICS (2023)

Letter Clinical Neurology

CBD diagnostic criteria: exclusions as important as inclusions

Irene Litvan, Anthony E. Lang, Melissa Armstrong

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2023)

Article Clinical Neurology

Basal Ganglia Atrophy as a Marker for Prodromal X-Linked Dystonia-Parkinsonism

Henrike Hanssen, Cid C. E. Diesta, Marcus Heldmann, Jackson Dy, Jeffrey Tantianpact, Julia Steinhardt, Rosanna Sauza, Hans T. S. Manalo, Andreas Sprenger, Charles Jourdan Reyes, Raphael Tuazon, Bjoern-Hergen Laabs, Aloysius Domingo, Raymond L. Rosales, Christine Klein, Thomas F. Muente, Ana Westenberger, Jean Q. Oropilla, Norbert Brueggemann

Summary: In this study, it was found that X-linked dystonia-parkinsonism has basal ganglia atrophy and iron accumulation before the clinical onset. These findings highlight the potential of early diagnosis and the importance of understanding the prodromal phase of the disease.

ANNALS OF NEUROLOGY (2023)

Article Clinical Neurology

Mitochondrial DNA heteroplasmy distinguishes disease manifestation in PINK1/PRKN-linked Parkinson's disease

Joanne Trinh, Andrew A. Hicks, Inke R. Koenig, Sylvie Delcambre, Theresa Lueth, Susen Schaake, Kobi Wasner, Jenny Ghelfi, Max Borsche, Carles Vilarino-Gueell, Faycel Hentati, Elisabeth L. Germer, Peter Bauer, Masashi Takanashi, Vladimir Kostic, Anthony E. Lang, Norbert Brueggemann, Peter P. Pramstaller, Irene Pichler, Alex Rajput, Nobutaka Hattori, Matthew J. Farrer, Katja Lohmann, Hansi Weissensteiner, Patrick May, Christine Klein, Anne Gruenewald

Summary: Trinh et al. found that PINK1/PRKN mutations increase the risk of mitochondrial DNA variant accumulation in a dose- and disease-dependent manner. Monoallelic mutation carriers can be distinguished by the level of heteroplasmic mtDNA variants. Biallelic mutations in PINK1/PRKN lead to recessive Parkinson's disease.

BRAIN (2023)

Letter Clinical Neurology

Frequency of non-motor symptoms in Parkinson?s disease patients carrying the E326K and T369M GBA risk variants

Tatiana Usnich, Maria Olmedillas, Nathalie Schell, Jefri J. Paul, Filipa Curado, Snezana Skobalj, Ilona Csoti, Sibel Ertan, Doreen Gruber, Simone Zittel, Esther Sammler, Stuart H. Isaacson, Andrea A. Kuehn, David J. Pedrosa, Kathrin Reetz, Meike Kasten, Arndt Rolfs, Peter Bauer, Volha Skrahina, Christine Klein, Norbert Brueggemann

PARKINSONISM & RELATED DISORDERS (2023)

Letter Clinical Neurology

Dystonia with myoclonus and vertical supranuclear gaze palsy associated with a rare GNB1 variant

Nikolai Gil D. Reyes, Daniel G. Di Luca, Vanda McNiven, Anthony E. Lang

Summary: GNB1 encephalopathy is a rare neuro-developmental syndrome caused by pathogenic variants in the GNB1 gene. It is characterized by global developmental delay and co-occurrence of movement disorders, with dystonia being the most common. Other rare phenomenologies include myoclonus, tics, chorea, ataxia, and oculomotor abnormalities. This case report presents a unique phenotype of GNB1 encephalopathy caused by a de novo mutation in exon 11, with symptoms of dystonia, myoclonus, and vertical supranuclear gaze palsy.

PARKINSONISM & RELATED DISORDERS (2023)

Article Clinical Neurology

A KMT2B Frameshift Variant Causing Focal Dystonia Restricted to the Oromandibular Region After Long-Term Follow-up

Alfand Marl F. Dy Closas, Katja Lohmann, Ai Huey Tan, Norlinah Mohamed Ibrahim, Jia Lun Lim, Yi Wen Tay, Kalai Arasu Muthusamy, Azlina Binti Ahmad-Annuar, Christine Klein, Shen -Yang Lim

Summary: KMT2B-linked dystonia (DYT-KMT2B) is a childhood-onset dystonia syndrome that commonly progresses from the lower limbs to the upper limbs and eventually affects the craniocervical region. It is now recognized as one of the more common monogenic causes of dystonia syndromes. This report presents an atypical case of DYT-KMT2B with oromandibular dystonia as the initial symptom, which remained localized to this region for three decades. This is the first reported case of DYT-KMT2B from Southeast Asia and provides further evidence for the pathogenic impact of the KMT2B c.6210_6213delTGAG variant.

JOURNAL OF MOVEMENT DISORDERS (2023)

Article Biochemistry & Molecular Biology

Role of Ceramides and Sphingolipids in Parkinson's Disease

Melissa Vos, Christine Klein, Andrew A. Hicks

Summary: Sphingolipids, a subset of bioactive lipids, play a crucial role in proper neuronal function and are involved in almost all biological processes. Recent studies have found alterations in sphingolipids in patients with Parkinson's disease (PD), suggesting an important interaction between sphingolipids and PD-related cellular processes. This article discusses the role of sphingolipids in mitochondrial dysfunction, autophagy defects, and abnormal endosomal activity in PD.

JOURNAL OF MOLECULAR BIOLOGY (2023)

Article Clinical Neurology

Distinguishing functional from primary tics: a study of expert video assessments

Antigony Rigas, Tina Mainka, Tamara Pringsheim, Alexander Muenchau, Irene Malaty, Yulia Worbe, Andrea E. Cavanna, Andrew John Lees, Anthony E. Lang, Davide Martino, Christos Ganos

Summary: This study revealed that the diagnostic distinction between primary and functional tics is often difficult, even for expert clinicians, in the absence of clinical information.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2023)

Article Clinical Neurology

The Lessebo Effect in Disease Modification Trials in Parkinson's Disease

Tiago A. Mestre, Michael P. McDermott, Raquel Lobo, Joaquim J. Ferreira, Anthony E. E. Lang

Summary: This study evaluated the "lessebo effect" in disease modification trials in Parkinson's disease and found that it did not exist in these trials. However, the use of placebo instead of an active comparator was a limitation. Prospective measurement of expectation of benefit could help assess the various impacts of placebo use.

MOVEMENT DISORDERS (2023)

Letter Clinical Neurology

Targeting alpha-Synuclein: A Further Viewpoint

Anthony E. Lang

MOVEMENT DISORDERS (2023)

Article Clinical Neurology

Classification and staging of Parkinson's disease using video-based eye tracking

Donald C. Brien, Heidi C. Riek, Rachel Yep, Jeff Huang, Brian Coe, Corson Areshenkoff, David Grimes, Mandar Jog, Anthony Lang, Connie Marras, Mario Masellis, Paula McLaughlin, Alicia Peltsch, Angela Roberts, Brian Tan, Derek Beaton, Wendy Lou, Richard Swartz, Douglas P. Munoz

Summary: A simple and non-invasive test was developed using video-based eye tracking and machine learning, which showed high sensitivity in detecting the stages of Parkinson's Disease and cognitive impairment. The classifier reached a sensitivity of 83% and a specificity of 78%.

PARKINSONISM & RELATED DISORDERS (2023)

Article Neurosciences

Molecular phenotypes of mitochondrial dysfunction in clinically non-manifesting heterozygous PRKN variant carriers

Maria Paulina Castelo Rueda, Alessandra Zanon, Valentina Gilmozzi, Alexandros A. Lavdas, Athina Raftopoulou, Sylvie Delcambre, Fabiola Del Greco, Christine Klein, Anne Gruenewald, Peter P. Pramstaller, Andrew A. Hicks, Irene Pichler

Summary: Homozygous or compound heterozygous variants in PRKN are causal for PD with highly penetrant symptom expression, while heterozygous variants may predispose to PD with reduced penetrance, through altered mitochondrial function. We generated lymphoblasts and hiPSC-derived neurons from non-manifesting heterozygous PRKN variant carriers and tested them for mitochondrial functionality. We identified molecular phenotypes that might be used to monitor heterozygous PRKN variant carriers during the prodromal phase and to test potential neuroprotective therapies.

NPJ PARKINSONS DISEASE (2023)

Article Clinical Neurology

Deep Brain Stimulation of the Globus Pallidus Internus and Externus in Multiple System Atrophy

Daniel G. Di Luca, Carolina Ramirez-Gomez, Jurgen Germann, Brendan Santyr, Alexandre Boutet, Luka Milosevic, Anthony E. Lang, Suneil K. Kalia, Andres M. Lozano, Alfonso Fasano

Summary: This study aimed to evaluate the safety and efficacy of deep brain stimulation on the globus pallidus pars interna and externa in MSA-P patients. The surgery did not result in major complications, but did not provide significant clinical benefit as measured by MDS-UPDRS III.

MOVEMENT DISORDERS (2023)

No Data Available